The countdown to Novo Nordisk’s September 21 capital markets day is shaping up to be anything but routine. With the Danish pharma giant’s shares hovering near multi-month lows, the event was always going to carry weight — but a fresh wave of bearish analyst calls, intensifying US competition, and a regulatory filing in Beijing have turned it into a genuine inflection point for the company’s growth narrative.
The stock closed Friday at €40.09, down 1.8 percent on the session, leaving it roughly 27 percent below its 52-week high of €54.86 touched back in January. Year-to-date the shares have shed 8.9 percent, while the twelve-month decline stands at a steeper 17 percent. The equity is now trading essentially at its 200-day moving average of €40.16, with an RSI of 48.2 suggesting neither oversold nor overbought conditions — technicals that offer little directional clarity ahead of the investor gathering.
Deutsche Bank Turns Decisively Bearish
The most conspicuous red flag comes from Deutsche Bank, where analyst Emmanuel Papadakis has downgraded the stock from Hold to Sell, trimming the price target from DKK 290 to DKK 265. His rationale centers on a lackluster second-quarter print, cautious forward guidance, and softer-than-expected Wegovy sales. Papadakis has also cut his medium-term revenue estimates, voicing fundamental doubts about the company’s growth trajectory — skepticism he explicitly framed with the upcoming capital markets day in mind.
The timing is awkward for management. The September 21 event is supposed to provide clarity on future growth strategy, yet the Deutsche Bank downgrade — delivered just before the gathering — has effectively pre-framed the occasion as a credibility test. If the bank’s pessimism proves well-founded, the event could become less a showcase and more a defensive exercise.
A Two-Front Competitive Squeeze
The bearish case is buttressed by competitive developments on both sides of the Atlantic. In the UK, Eli Lilly has launched its oral weight-loss drug Foundayo, landing at a moment when Novo Nordisk’s own Wegovy tablet has secured a positive recommendation from the European Medicines Agency but is still awaiting the European Commission’s final decision. The head-to-head comparison of two oral anti-obesity pills is expected to intensify pricing and innovation pressure in the months ahead.
Meanwhile, across the pond, Lilly has received FDA approval for Mounjaro to reduce cardiovascular risk in type-2 diabetes patients with elevated heart risk. That label expansion sharpens the contest in the GLP-1 arena, where Novo Nordisk has traditionally held a leading position with Wegovy and Rybelsus. Analysts characterize this as a structural headwind that could weigh on the company’s growth prospects for years.
The competitive strain is compounded by pricing concessions in the US market. Reuters has reported that Novo Nordisk agreed in November to cut US prices for its semaglutide products, including Wegovy and Ozempic. Through Medicare, Medicaid, and a direct-distribution channel dubbed TrumpRx, the drugs will be offered at $350 per month. Insulin products NovoLog and Tresiba are slated for a $35 monthly price point via the same channel. These concessions secure access to a critical market but inevitably compress profitability in what has been the company’s primary growth engine.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
China Emerges as a Potential Counterweight
Against this backdrop of pricing pressure and intensifying rivalry, Asia offers a glimmer of optimism. China’s drug regulator has accepted the filing for the oral version of Wegovy, a development first reported by Reuters. Novo Nordisk has declined to provide a timeline for potential approval, but the acceptance itself opens the door to the world’s second-largest pharmaceutical market — one with among the largest patient populations for obesity and diabetes treatments globally.
Reuters characterized the move as an additional expansion pathway that could partially offset the growth concerns emanating from Europe and the United States. The filing arrives just as the Wegovy tablet launches in Germany, giving the company a two-pronged push for its oral formulation across key markets.
Sell Ratings Pile Up, Though Not Everyone Agrees
Deutsche Bank is not alone in its bearish stance. Citi reaffirmed its Sell rating in early September with a price target of DKK 265, pointing to a slowdown in GLP-1 prescription trends. JPMorgan, however, strikes a more measured tone: following conversations with management, the bank maintained its Neutral rating with a DKK 275 target, citing the Wegovy tablet launch as a potential catalyst.
The analyst community’s division underscores the uncertainty surrounding Novo Nordisk’s near-term prospects. The bears point to decelerating prescription data and margin erosion from US price cuts; the bulls counter that the oral formulation’s rollout — now spanning Germany with China in the pipeline — represents an underappreciated growth vector.
For now, the stock sits in a holding pattern, caught between competing narratives. One story line, favored by the bears, emphasizes weakening Wegovy momentum and a formidable competitive landscape. The other, championed by the more optimistic voices, highlights the China filing as an open-ended catalyst with substantial long-term potential. The September 21 capital markets day will determine which of these two versions management can more persuasively defend — and whether the market’s patience has finally run its course.
Ad
Novo Nordisk Stock: Buy or Sell?! New Novo Nordisk Analysis from September 6 delivers the answer:
The latest Novo Nordisk figures speak for themselves: Urgent action needed for Novo Nordisk investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from September 6.
Novo Nordisk: Buy or sell? Read more here...
